Galedra
Source
Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial PRIMARY_TEXT retrieval pending
Retrieval by Galedra
Not yet fetched. Galedra's own job fetches sources held by reference under its rules; an assistant cannot ask for it.
Claims from this source
No claims have been extracted from this source yet.
Locations
| Locator | Excerpt |
|---|---|
QUOTE {} | The HERBOT study was an open-label, single-arm, phase 1b/2 trial performed at 12 academic cancer centers in South Korea to evaluate the efficacy and safety of a quadruplet regimen ... as first-line therapy for HER2-positive unresectable ... |
QUOTE {} | DCR was the proportion of subjects with confirmed CR, PR and stable disease for at least 4 weeks. |
QUOTE {} | All included participants were treatment-naive for advanced or metastatic diseases. ... the predominant cancer subtype was GBC (72.5%). |
QUOTE {} | This study had some limitations. Firstly, the single-arm, nonrandomized design without a control arm limits definitive comparison to the current standard of care. |